zealand amylin - Search News

Roche, Obesity and Zealand

Reuters on MSN · 1d

Roche secures Zealand obesity drug candidate for up to $5.3 billion

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming weight-loss market.

Zacks Investment Research on M… · 6h

NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand

Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 billion with Denmark’s Zealand Pharma to co-develop its lead obesity candidate petrelintide.

Medical Marketing & Media · 9h

Roche strikes $5.3B obesity treatment deal with Zealand Pharma

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to develop its obesity drug candidate.

Fierce Biotech1d

Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

1d

Roche And Zealand Team Up To Develop Petrelintide

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

1d

Zealand Pharma to pay $350M to Roche in petrelintide collaboration, license pact

Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results